ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO2372

Pharmacological Inhibition of Vanin 1 Is Not Protective in Models of Acute and Chronic Kidney Disease

Session Information

Category: Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)

  • 1800 Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)


  • Unterschemmann, Kerstin Dr., Bayer AG, Leverkusen, Nordrhein-Westfalen, Germany
  • Ehrmann, Alexander, Bayer AG, Leverkusen, Nordrhein-Westfalen, Germany
  • Herzig, Ina Daniela, Bayer AG, Leverkusen, Nordrhein-Westfalen, Germany
  • Andreevski, Anna Lena, Bayer AG, Leverkusen, Nordrhein-Westfalen, Germany
  • Schmeck, Carsten, Bayer AG, Leverkusen, Nordrhein-Westfalen, Germany
  • Eitner, Frank, Bayer AG, Leverkusen, Nordrhein-Westfalen, Germany
  • Grundmann, Manuel, Bayer AG, Leverkusen, Nordrhein-Westfalen, Germany

Dysregulated oxidative stress handling is a hallmark of acute and chronic kidney diseases. The pantetheinase Vanin-1 is highly expressed in tubular cells and its reaction product cysteamine is described to negatively affect redox homeostasis by inhibiting the replenishment of cellular anti-oxidative glutathione stores. The aim of this study was to elucidate whether pharmacological inhibition of Vanin-1 protects mice from acute or chronic kidney injury.


C57Bl6 mice undergoing ischemia reperfusion injury and Col4α3-/- (Alport syndrome) mice were treated orally for 1d and 3wk, respectively, with a potent and selective Vanin-1 inhibitor or placebo. In vitro oxidative stress insult was mimicked in human renal proximal tubular epithelial cells either chemically or by hypoxia/reoxygenation. Kidney function was determined by serum and urinary creatinine as well as serum urea and urinary albumin. Furthermore, mRNA and protein expression, Vanin-1 activity, oxidative stress level and tubular apoptosis were monitored.


Oxidative stress levels were elevated in all models. Treatment with the Vanin-1 inhibitor resulted in ample systemic compound exposure and full inhibition of Vanin-1 activity in kidney tissue in vivo. However, this did not translate to a relevant reduction of oxidative stress level. Moreover, kidney function (serum Crea, blood urea, albuminuria), fibrosis marker gene expression and tubular cell apoptosis were not improved by Vanin-1 inhibition.


Pharmacological inhibition of Vanin-1 is insufficient to protect kidneys from oxidative stress insults contributing to acute and chronic kidney injury. The biological relevance of pharmacological Vanin-1 inhibition for the treatment of kidney diseases remains to be proven.


  • Commercial Support